Spots Global Cancer Trial Database for hcc
Every month we try and update this database with for hcc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) | NCT00960167 | Hepatocellular ... | 3DCRT or IMRT | 18 Years - 70 Years | National Taiwan University Hospital | |
| Hepatocarcinoma Recurrence on the Liver Study - Part2 | NCT04053231 | Liver Cancer Surgery Recurrence Tumo... Cirrhosis | liver resection | 18 Years - | University of Milano Bicocca | |
| Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | NCT04220944 | Hepatic Carcino... | Sintilimab Microwave Ablat... TACE | 18 Years - 80 Years | Shanghai Zhongshan Hospital | |
| Artificial Intelligence and Hepatocellular Carcinoma | NCT05637788 | HCC | CT Scan Radiomi... | 18 Years - | Humanitas Clinical and Research Center | |
| Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma | NCT04847726 | Hepatocellular ... | contrast enhanc... Dynamic CT Liver MRI | 18 Years - | Seoul National University Hospital | |
| Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma | NCT03807947 | Hepatocellular ... Hepatocellular ... | Radial TAE - Bl... Transfemoral TA... | 40 Years - 90 Years | Humanitas Clinical and Research Center | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). | NCT02026362 | Hepatocellular ... | MASCT:Multiple ... The foundation ... | 20 Years - 70 Years | HRYZ Biotech Co. | |
| A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers | NCT02272504 | Cirrhosis Chronic Liver D... | 18 Years - | Wako Life Sciences | ||
| Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) | NCT05660213 | Unresectable He... | Huaier granule Atezolizumab + ... Camrelizumab+Ap... Sintilimab+Beva... | 18 Years - | Fudan University | |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | NCT05056337 | Hepatocellular ... | Lenvatinib 4 MG... Toripalimab TACE | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | NCT01273662 | Hepatocellular ... | AG-013736 | 18 Years - | National Taiwan University Hospital | |
| Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | NCT01858207 | Hepatocellular ... | Transcatheter A... Radiofrequency ... Doxorubicin | 18 Years - | Chang Gung Memorial Hospital | |
| Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC | NCT06059885 | Liver Neoplasms | Tislelizumab pl... | 18 Years - | Beijing 302 Hospital | |
| Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. | NCT02715492 | HCC | LMWH TACE | 40 Years - 60 Years | Tanta University | |
| Optimizing Y90 Therapy for Radiation Lobectomy | NCT04390724 | HCC Resection Transplant Metastatic Canc... Adult Primary L... | Y90 radioemboli... | 18 Years - | Northwestern University | |
| To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | NCT05783570 | Advanced Hepato... | EU307 CAR-T Cel... | 19 Years - | Eutilex | |
| A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | NCT01356628 | Advanced Hepato... HCC Liver Cancer | PD-0332991 | 18 Years - | Thomas Jefferson University | |
| Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | NCT02513199 | Hepatocellular ... | SBRT TACE | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir | NCT03247296 | Hepatitis C | Sofosbuvir 400 ... | 18 Years - 75 Years | MTI University | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | NCT03516071 | Hepatocellular ... | Brivanib 800 mg... Brivanib 400 mg... | 18 Years - 75 Years | Zai Lab (Hong Kong), Ltd. | |
| A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | NCT03634683 | Recurrent Hepat... | LioCyx | 21 Years - | Lion TCR Pte. Ltd. | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06133062 | Hepatocellular ... | Atezolizumab Bevacizumab Proton radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 | NCT00775073 | Hepatocellular ... | Everolimus, Bev... | 18 Years - | Treiber, Gerhard | |
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC) | NCT01308645 | Hepatocellular ... | SB injection | 18 Years - | SBPharmaceutical IND, Co., LTD | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | NCT01721941 | Hepatocellular ... | Phase I Dose le... Phase I dose le... Phase I Dose le... Phase I Dose le... | 18 Years - | Scripps Clinic Cancer Center | |
| Study of Serum Tumor Markers of HBV Associated HCC | NCT05825196 | HCC | tumor tissue an... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| NeuWave HCC China Study | NCT03783871 | Liver Tumor Hepatocellular ... | Microwave ablat... | 18 Years - | Ethicon, Inc. | |
| Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer | NCT03186898 | Unrectable or L... | Proton Therapy ... Photon Therapy ... | 18 Years - | NRG Oncology | |
| Temsirolimus as Second-line Therapy in HCC | NCT01567930 | Unresectable or... | Temsirolimus | 18 Years - | University of Tennessee Cancer Institute | |
| Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | NCT04553458 | Hepatocellular ... | Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre... | 18 Years - | Sohag University | |
| HCC Patient Preferences in Japan | NCT02616692 | Hepatocellular ... | Hepatocellular ... | 20 Years - | Bayer | |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® | NCT00877136 | Liver Tumors Hepatocellular ... Hepatoma Neoplasms | TheraSphere® | 18 Years - | St. Joseph Hospital of Orange | |
| Protein Biomarker in Hepatocellular Carcinoma | NCT00465842 | Normal Voluntee... Hepatitis Liver Cirrhosis Hepatocellular ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||
| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | NCT05212922 | HCC NSCLC Stage III... NSCLC Stage IV | YH001 + Toripal... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | NCT01272557 | Liver Carcinoma | Doxorubicin Sorafenib | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| BAY1238097, First in Man | NCT02369029 | Neoplasms | BAY 1238097 | 18 Years - | Bayer | |
| Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients | NCT04736121 | Unresectable He... BCLC Stage A He... BCLC Stage B He... BCLC Stage C He... | Resin microsphe... | 18 Years - | Sirtex Medical | |
| Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | NCT05117957 | Advanced Hepato... | Sorafenib | 20 Years - | National Cancer Center, Korea | |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG) | NCT01393197 | Carcinoma, Hepa... | Therapeutic Che... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers | NCT02272504 | Cirrhosis Chronic Liver D... | 18 Years - | Wako Life Sciences | ||
| Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study | NCT06024252 | HCC | TACE | 18 Years - | Zhongda Hospital | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) | NCT05781568 | HCC Cirrhosis, Live... NAFLD HBV HCV | Biomarker dosag... | - | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | |
| Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | NCT04601428 | Hepatocellular ... | IA therapy of H... | 18 Years - | Koo Foundation Sun Yat-Sen Cancer Center | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | NCT05493332 | Hepatocellular ... | HAIC(FOLFOX) Oxaliplatin Leucovorin Fluorouracil Toripalimab Donafenib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility | NCT03342677 | Hepatocellular ... | Primovist MRI | 18 Years - | University Health Network, Toronto | |
| Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma | NCT00983541 | Cancer | Fluorouracil (5... Brachytherapy o... Gemcitabine | 18 Years - | University of Utah | |
| Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy | NCT03817736 | HCC | TACE SBRT Immune Checkpoi... | 18 Years - 75 Years | The University of Hong Kong | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| Predictors of Sorafenib Response in HCC | NCT05967429 | Hepatocellular ... | The neutrophil-... Prognostic nutr... | - | Sohag University | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway | NCT01892072 | Hepatocellular ... | surgical treatm... | 16 Years - 80 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Pembrolizumab in Hepatocellular Carcinoma | NCT03419481 | HCC | pembrolizumab | 18 Years - | Chinese University of Hong Kong | |
| A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | NCT05417932 | Hepatitis B Vir... Hepatocellular ... | SCG101 | 18 Years - 70 Years | SCG Cell Therapy Pte. Ltd. | |
| RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode | NCT02806076 | Carcinoma, Hepa... | No-touch RFA ar... Conventional tu... | 20 Years - 85 Years | Seoul National University Hospital | |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | NCT01488487 | Advanced Adult ... | Everolimus Pasireotide | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) | NCT00397540 | Carcinoma, Hepa... Chronic Hepatit... | PEIT RFTA | 19 Years - 80 Years | Seoul National University Hospital | |
| Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments | NCT05443217 | Liver Cancer Microbiota Adverse Event Prognosis Efficacy | questionnaire s... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Optimization for Regorafenib in HCC | NCT04476329 | Hepatocellular ... | Regorafenib 40 ... | 18 Years - | SC Liver Research Consortium, LLC | |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | NCT05201404 | Hepatocellular ... Cirrhosis | Namodenoson Placebo | 18 Years - | Can-Fite BioPharma | |
| An Individualized Anti-Cancer Vaccine Study in Patients With HCC | NCT01995227 | Hepatocellular ... | AlloVax CRCL AlloStim | 18 Years - | Immunovative Therapies, Ltd. | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| LifePearl-Doxo Pharmacokinetic (PK) Study | NCT02548780 | HCC Hepatocellular ... | Chemoembolizati... Pharmacokinetic... | 18 Years - | Terumo Europe N.V. | |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | NCT00997022 | Hepatocellular ... | Sorafenib | 18 Years - | Columbia University | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumor Treatment With Percutaneous Ablation | NCT04123340 | HCC | Additional intr... | 18 Years - 99 Years | Leiden University Medical Center | |
| Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) | NCT05781568 | HCC Cirrhosis, Live... NAFLD HBV HCV | Biomarker dosag... | - | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
